Abdala (vaccine)
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Other names | ABDALA |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Abdala, technical name CIGB-66, is a COVID-19 vaccine candidate developed by the Center for Genetic Engineering and Biotechnology in Cuba.[1][2] This vaccine candidate, named after a patriotic drama by Cuban independence hero José Martí, is a protein subunit vaccine containing COVID-derived proteins that trigger an immune response.[3] However, none of the clinical trial full results have been published. This candidate followed a previous one called CIGB-669 (MAMBISA).[4]
The vaccine is one of two Cuba-developed COVID-19 vaccines in Phase III trials.[5][6][7]
Clinical research
Phase I/II
In July 2020, CIGB-66 commenced phase I/II clinical trials.[8]
Phase III
The Phase III trial compares 3 doses of the vaccine administered at 0, 14 and 28 days against a placebo, with the primary outcome measuring the proportion of cases reported for each group 14 days after the third dose.
The trial was registered on 18 March 2021. The first dose was administered on 22 March and by April 4, the 48,000 participants had received their first dose,[9][10] and second doses started being administered from April 5.[11][12] Third doses have started being administered on 19 April[13][14][15] and on May 1, 97% of the original participants had received their 3 doses, the others 3% were lost in the process.
Intervention study
124,000 people aged 19 to 80 received 3 doses of the vaccine as part of an intervention study, with the primary outcome measuring the proportion of cases and deaths for the vaccinated compared to the unvaccinated population.[16]
A wider intervention study with the 1.7 million inhabitants of Havana is expected to start in May with the Abdala and Soberana 2 vaccine.[17]
Efficacy
On June 22, official Cuban government sources announced that the results of an initial study by the Cuban Center for Genetic Engineering and Biotechnology found the vaccine, administered in 3 doses spaced 2 weeks apart, had a 92.28% efficacy rate at preventing COVID-19. This measure of efficacy includes infection by the initial strain of SARS-CoV-2, as well as the mutant Alpha, Beta, and Gamma strains.[18]
Production outside Cuba
Venezuela has claimed that it will manufacture the vaccine[19] but, as of May 2, 2021, this claim had not yet materialised.[20] State-owned EspromedBIO will manufacture the vaccine but some "arrangements" are needed to start production.[21] In April, Nicolás Maduro said that a capacity of 2 Million doses per month is hoped to be reach by "August, September approximately".[22] In June 2021, Vietnam's Ministry of Health announced that negotiations were ongoing between Cuba and Vietnam for Abdala vaccine production. The Institute of Vaccines and Medical Biologicals (IVAC) was named as the focal point for receiving technology transfer.[23]
References
- ^ "ABDALA Clinical Study - Phase III". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Retrieved 22 March 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ "ABDALA Clinical Study". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Retrieved 22 March 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ Yaffe H (31 March 2021). "Cuba's five COVID-19 vaccines: the full story on Soberana 01/02/Plus, Abdala, and Mambisa". LSE Latin America and Caribbean blog. Retrieved 31 March 2021.
- ^ "MAMBISA Study". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Retrieved 22 March 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ "Three-shot Cuban COVID-19 vaccine candidate moves forward in phase III". www.bioworld.com. Retrieved 10 April 2021.
- ^ "Cuba's Abdala COVID-19 vaccine enters phase 3 clinical trial - Xinhua | English.news.cn". www.xinhuanet.com. Retrieved 10 April 2021.
- ^ Zimmer C, Corum J, Wee SL. "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 10 April 2021.
- ^ "ABDALA Clinical Study". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Retrieved 21 March 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ BioCubaFarma (4 April 2021). "[Translated] "The application of the 1st dose of #Abdala, in volunteer 48 thousand, of the Phase III Clinical Trial. Next Monday, April 5, the application of the 2nd dose of this vaccine candidate begins. #VcaunasCubanasCovid19 ."". Twitter. Retrieved 10 April 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ "Covid Check-in: Cuba's Homegrown Vaccines". AS/COA. Retrieved 10 April 2021.
- ^ BioCubaFarma (5 April 2021). "[Translated] "The application of the 2nd dose of the vaccine candidates begins today #Abdala and #Soberana02 , as part of the 3rd phase of the clinical trial. Workers of @Emcomed1 in Havana and eastern provinces, from very early hours they carry out their distribution until the vaccination centers"". Twitter (in Spanish). Retrieved 10 April 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ "Two Cuban Vaccines Start Second Dose Phase III Trials". Kawsachun News. 5 April 2021. Retrieved 10 April 2021.
- ^ "Abdala: Comienza tercera dosis en el Oriente cubano". www.cuba.cu (in Spanish). Retrieved 21 April 2021.
- ^ BioCubaFarma. "[Translated] "Application of the 3rd dose of the vaccine candidate begins #Abdala in the provinces of Granma, Santiago de Cuba and Guantánamo. The application of the 2nd dose of #Soberana02 within the framework of the EC Phase III.#VacunasCubanasCovid19". Twitter. Retrieved 21 April 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ Noticias, Agencia Cubana de. "Convergen múltiples voluntades para éxito de estudio Abdala en Bayamo". ACN (in European Spanish). Retrieved 21 April 2021.
- ^ "ABDALA-Intervention | Registro Público Cubano de Ensayos Clínicos". rpcec.sld.cu. Retrieved 10 April 2021.
- ^ Ministerio de Salud Pública en Cuba. "Sitio oficial de gobierno del Ministerio de Salud Pública en Cuba". Sitio oficial de gobierno del Ministerio de Salud Pública en Cuba (in European Spanish). Retrieved 23 April 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ "Abdala, con tres dosis, tiene una eficacia de 92,28 % (+Video)". Granma.cu (in Spanish). Retrieved 22 June 2021.
- ^ "Cuba says it's 'betting it safe' with its own Covid vaccine". NBC News. Retrieved 10 April 2021.
- ^ "Maduro struggles to make his grand vaccine promise". Eminetra.co.uk. 2 May 2021. Retrieved 3 May 2021.
{{cite web}}: CS1 maint: url-status (link) - ^ "Venezuela producirá la vacuna cubana anticovid Abdala". www.efe.com (in Spanish). Retrieved 3 May 2021.
- ^ "Venezuela to produce Cuban COVID vaccine: Maduro". Aljazeera.com. Al Jazeera and news agencies. 12 April 2021. Retrieved 23 June 2021.
We've signed an agreement to produce in our laboratories… two million vaccines a month of the Abdala vaccine… for August, September, approximately,
- ^ Ministry of Health Vietnam (16 June 2021). "Bộ trưởng Bộ Y tế đàm phán với Cuba về hợp tác sản xuất vaccine". giadinh.net.vn (in Vietnamese). Retrieved 17 June 2021.
{{cite web}}: CS1 maint: url-status (link)
External links
